Aimmune Therapeutics Inc. (NASDAQ:AIMT) traded up 4.1% during mid-day trading on Wednesday . The company traded as high as $11.18 and last traded at $11.16, with a volume of 51,619 shares traded. The stock had previously closed at $10.72.

Several research firms recently weighed in on AIMT. Zacks Investment Research upgraded Aimmune Therapeutics from a “hold” rating to a “buy” rating and set a $16.00 price target for the company in a research note on Friday, May 20th. Piper Jaffray Cos. reiterated an “overweight” rating and set a $38.00 price target on shares of Aimmune Therapeutics in a research note on Tuesday, May 17th. Wedbush reiterated an “outperform” rating and set a $42.00 price target on shares of Aimmune Therapeutics in a research note on Monday, June 13th. Finally, Bank of America Corp. reiterated a “buy” rating on shares of Aimmune Therapeutics in a research note on Monday, May 16th. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. The company presently has an average rating of “Buy” and a consensus price target of $33.40.

The stock’s market cap is $471.48 million. The company’s 50-day moving average price is $12.17 and its 200 day moving average price is $14.21.

Aimmune Therapeutics (NASDAQ:AIMT) last announced its quarterly earnings data on Monday, May 16th. The company reported ($0.37) EPS for the quarter, beating the consensus estimate of ($0.40) by $0.03. Equities research analysts predict that Aimmune Therapeutics Inc. will post ($1.70) earnings per share for the current fiscal year.

In related news, major shareholder Foresite Capital Fund Ii, L.P. sold 240,000 shares of the business’s stock in a transaction on Tuesday, May 31st. The shares were sold at an average price of $15.23, for a total value of $3,655,200.00. The sale was disclosed in a legal filing with the SEC, which is accessible through this link.

A hedge fund recently bought a new stake in Aimmune Therapeutics stock. TLP Group LLC bought a new position in Aimmune Therapeutics Inc. (NASDAQ:AIMT) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 2,781,259 shares of the company’s stock, valued at approximately $51,314,000. Aimmune Therapeutics comprises 40.9% of TLP Group LLC’s holdings, making the stock its largest position. TLP Group LLC owned 6.58% of Aimmune Therapeutics as of its most recent SEC filing.

Aimmune Therapeutics Inc, formerly Allergen Research Corporation, is a United States-based clinical-stage biopharmaceutical company. The Company focuses on therapeutic approach, including the development of proprietary candidates, for the treatment of peanut and other food allergies. The Company’s Characterized Oral Desensitization Immunotherapy (CODIT) is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.